Pallas Capital Advisors LLC Cuts Stake in Zoetis Inc. $ZTS

Pallas Capital Advisors LLC lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 84.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,385 shares of the company’s stock after selling 13,200 shares during the period. Pallas Capital Advisors LLC’s holdings in Zoetis were worth $300,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Diamond Hill Capital Management Inc. acquired a new position in shares of Zoetis during the third quarter valued at approximately $394,010,000. Nordea Investment Management AB boosted its stake in shares of Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after acquiring an additional 2,179,578 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Zoetis by 83.4% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company’s stock worth $394,746,000 after acquiring an additional 1,227,085 shares during the last quarter. Corient Private Wealth LLC increased its position in shares of Zoetis by 85.9% during the second quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock worth $400,619,000 after purchasing an additional 1,191,840 shares in the last quarter. Finally, First Trust Advisors LP increased its position in shares of Zoetis by 342.1% during the third quarter. First Trust Advisors LP now owns 1,485,459 shares of the company’s stock worth $217,352,000 after purchasing an additional 1,149,467 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

NYSE ZTS opened at $117.45 on Thursday. The stock’s fifty day moving average is $122.97 and its two-hundred day moving average is $128.49. The firm has a market capitalization of $49.58 billion, a P/E ratio of 19.51, a price-to-earnings-growth ratio of 1.80 and a beta of 0.95. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis Inc. has a fifty-two week low of $113.29 and a fifty-two week high of $172.23.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. During the same period last year, the company earned $1.40 EPS. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.8%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Analyst Ratings Changes

A number of research analysts have weighed in on ZTS shares. Barclays initiated coverage on Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective on the stock. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. UBS Group set a $136.00 price target on shares of Zoetis in a research note on Thursday, January 29th. Morgan Stanley set a $160.00 price target on shares of Zoetis in a research report on Thursday, December 18th. Finally, HSBC set a $140.00 price objective on shares of Zoetis in a research note on Wednesday, December 10th. Six equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.